ImageneBio Stock: Why Analysts See 150% Upside Despite Competitor Setbacks
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
Already have an account? Sign in.
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
Be the first to know when deals break, stocks move, or biotech headlines hit.